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Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control 
proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological 
concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor 
vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells 
(transgenic mice overexpressing PAI-1) or by tumor cells (after transfection with murine PAI-1 cDNA).         
This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor 
angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did 
not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1. 
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The Plasminogen/Plasmin system is one of the most efficient enzymatic systems used by tumor and endothelial 
cells to break down the extracellular matrix and to invade host tissue (Stephens et al., 1998; Andreasen et al., 
2000; Rakic et al., 2003). Urokinase-type (uPA) and tissue-type plasminogen (tPA) activators both convert 
plasminogen to plasmin, which degrades matrix components and activates latent metalloproteinases and latent 
growth factors. Their main physiological inhibitor, Plasminogen activator inhibitor type 1 (PAI-1), has been 
considered for a long time as a cancer inhibitor (Soff et al., 1995; Stefansson et al., 2001). However, recently 
increasing evidence demonstrated a proangiogenic role of PAI-1. PAI-1 deficiency in mice has been reported to 
reduce angiogenesis in two models of tumor transplantation (Bajou et al.,  1998; Gutierrez et al., 2000), in the 
mouse aortic ring assay (Devy et al., 2002; Masson et al., 2002) and in the laser-induced choroidal 
neoangiogenesis assay (Lambert et al., 2001). PAI-1 is thought to contribute to angiogenesis by regulating 
plasmin-mediated proteolysis (Bajou et al., 2001; Devy et al., 2002) and/or by modulating cell migration 
(Kjoller et al., 1997; Deng et al., 1996, 2001; Isogai et al., 2001; Czekay et al., 2003). 
These findings emphasizing a proangiogenic and/or a promigratory effect of PAI-1 are in accordance with the 
clinical data indicating that high expression of PAI-1 in tumors correlates with poor prognosis for patients 
suffering from a variety of tumors (Andreasen et al., 2000; Foekens et al., 2000; Rakic et al., 2003). However, 
there are apparent discrepancies between these data and (1) the lack of impact of PAI-1 deficiency on metastasis 
of melanoma cells (Eitzman et al., 1996), on MMTV-Pym T-induced breast cancer progression (Almholt et al., 
2003), and (2) the antiangiogenic effect of PAI-1 observed in the chicken chorioallantoid membrane (CAM) 
(Stefansson et al., 2001) and in the Matrigel implant assay (McMahon et al., 2001). Taken together, these 
findings indicate that the role of PAI-1 as a determinant of tumoral angiogenesis might vary with experimental 
setting (tumor-type or injection-site dependent) and might depend on its cellular origin (tumor cells versus host 
cells). In addition, a dose-dependent effect of PAI-1 has been reported in vitro (Devy et al., 2002) and in vivo, in 
a model of choroidal neoangiogenesis (Lambert et al., 2003). 
In an attempt to explain these conflicting results, malignant PDVA keratinocytes overexpressing or not PAI-1 
were transplanted into mice lacking PAI-1 or expressing it at various levels. Their tumorigenicity and angiogenic 
phenotype were compared in the presence of different matrix components. 
PDVA cells failed to induce tumor growth when subcutaneously injected into PAI-1-/- mice 
The collagen gel used in the transplantation chamber model (Bajou et al., 1998) could be considered as abnormal 
conditions leading to artefactual results. Therefore, to investigate the putative effect of matrix components, 
PDVA cells were injected subcutaneously with Matrigel, into wild-type (PAI-1+/+) and PAI-1-deficient (PAI-1-/-) 
mice. At 1 month after cell inoculation into PAI-1+/+ mice, tumors were palpable in 30% of injected sites and 
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their volumes increased exponentially, reaching 1.4 cm3 after 60 days. At that time, tumor incidence was 70%. In 
contrast, no tumors were detected in PAI-1-/- mice even after 60 days (Figure 1). The protumorigenic effect of 
PAI-1 is thus independent to the extracellular matrix surrounding tumor cells. These observations agreed with 
the reduced tumor growth reported after subcutaneous injection of murine fibrosarcoma cells into PAI-1-/- mice 
(Gutierrez et al., 2000). However, they do not fit with the lack of effect of PAI-1 deficiency on the progression 
of virus oncogene (MMTV-Pym-T)-induced breast cancer (Almholt et al., 2003). A possible explanation for 
these conflicting results are that PAI-1 does not play a key role in the MMTV-PymT model, or that 
compensatory mechanisms take place during endogenous tumor development, but not after challenging mice by 
tumor transplantation. 
 
Figure 1 Primary tumor growth of malignant keratinocytes. PDVA cells (2 x 106 cells/site) were mixed with an 
equal volume of Matrigel (10mg/ml) and injected subcutaneously into PAI-1+/+ or PAI-1-/- mice. Tumor volume 
was calculated using the formula: width2 x length x 0.4 
 
 
Excess or absence of PAI-1 in the host-inhibited tumor invasion and vascularization 
PDVA cells cultured on a collagen gel were next transplanted into PAI-1-/-, transgenic mice overproducing PAI-1 
(Tg-PAI-1) at blood concentrations ranging from 17 ng/ml to more than 50 ng/ml, and their corresponding 
control mice (PAI-1+/+ or Tg-WT) producing PAI-1 at physiological concentration (from 2 to 4 ng/ml). At 2 
weeks after cell transplantation into wild-type mice (PAI-1+/+ and Tg-WT), malignant keratinocytes invaded the 
collagen gel, penetrated into host tissues and were surrounded by blood vessels (Figure 2a). In sharp contrast, in 
PAI-1-/- mice as well as in Tg-PAI-1 mice (Figure 2b), an inhibition of tumor cell invasion and vascularization 
was observed. In these conditions, blood vessels remained below the collagen gel and tumor cells failed to 
invade the host tissue. 
Quantification by image analysis showed that the average tumor invasion and angiogenesis were significantly 
reduced in PAI-1-/- and Tg-PAI-1 mice as compared to their corresponding control mice (PAI-1+/+ and Tg-WT, 
respectively) (Figure 2c). In Tg-PAI-1 mice, an inhibition of both tumor invasion and vascularization was 
observed independently of blood PAI-1 concentration. This suggests that an excess of PAI-1 (concentration 
higher than 17 ng/ml versus 2-4 ng/ml in WT mice) always leads to tumor reduction. Thus, an absence as well as 
an excess of host PAI-1 inhibit in vivo the tumor development and vascularization. These observations are 
consistent with the bell-shape effect of PAI-1 observed in vitro in the aortic ring assay (Devy et al., 2002) and in 
vivo, in a model of laser-induced choroidal neoangiogenesis (Lambert et al., 2003). By demonstrating that in 
vivo PAI-1 effects on tumor development and vascularization are dependent on its concentration, our findings 
resolve apparently conflicting data indicating that PAI-1 can inhibit as well as promote angiogenesis (Soff et al., 
1995; Bajou et al., 1998; Gutierrez et al., 2000; McMahon et al., 2001; Stefansson et al., 2001; Curino et al., 
2002). 
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Figure 2 Invasion and angiogenesis of malignant keratinocytes. PDVA cells (2 x 105) were plated on a collagen 
type I gel (4mg/ml) inserted in teflon rings, covered with a silicone transplantation chamber (Renner GmbH) and 
implanted onto the dorsal muscle fascia of mice (Bajou et al., 1998). Cells were transplanted for 2 weeks into 
PAI-1-/- mice, wild-type mice (a) and transgenic mice overexpressing PAI-1 under the control of adipocyte-
specific αP2 promoter (Tg-PAI-1 mice) (b) (Lijnen et al., 2004). Malignant cells were labeled in green with an 
anti-keratin antibody, while vessels were stained in red with an anti-collagen type IV antibody. Quantification of 
tumor invasion (i) (c) and angiogenesis (a) (d) was performed by morphometric measurements using a 
computer-assisted image analysis system (Olympus Micro Image version 3.0 for Windows 95/NT, Olympus 
Optical CO., Europe GmBH). 'i' = the depth of tumor cell invasion corresponding to the distance between the 
top of the tumor cell layer to the deepest front of tumor spread; 'a' = distance separating tumor cells from the 
front of migrating blood vessels, 'a' is inversely related to the degree of endothelial cell migration. A zero value 
means that vessels have reached the basal tumor layer, 'a' is negative when vessels did not reach the tumor cells, 
and positive when vessels were intermingled with tumor cells. In all, 10-12 measurements of each parameters  
('i' and 'a') were performed for each tumor (n = 8), and the mean values are reported. The horizontal bars 
represent median values, P-values were generated by ANOVA test (*P ≤ 0.05) 
 
 
Overexpression of PAI-1 by tumor cells reduced in vitro and in vivo tumor development, but did not 
compensate for PAI-1 deficiency in the host 
In our tumor transplantation system, the lack of tumor invasion and vascularization in PAI-1-deficient mice is a 
consequence of the absence of PAI-1 derived from host cells. Indeed, re-establishment of PAI-1 expression in 
host cells by adenovirus-mediated gene transfer restored the angiogenic and invasive phenotype of PDVA cells 
(Bajou et al., 1998, 2001). In order to determine whether an overproduction of PAI-1 by tumor cells could 
overcome the host deficiency, PDVA cells were transfected with murine PAI-1 cDNA. A significant increase of 
PAI-1 mRNA expression was assessed by RT-PCR (Figure 3a). PAI-1 overproduction was confirmed by 
immunostaining (data not shown) and ELISA analysis revealing a threefold increase of PAI-1 released by 
transfected cells. PAI-1 overexpression by PDVA cells led to a significant reduction of in vitro invasion                    
(P ≤ 0.05) (Figure 3b). An inhibition of tumor invasion and angiogenesis was observed when PAI-1-
overexpressing cells were transplanted into wild-type mice or PAI-1 transgenic mice (Tg-PAI-1) (P ≤ 0.025) 
(Figure 4a, b). Therefore, inhibition of tumor development was achieved by an overproduction of PAI-1 by 
tumor cells themselves (Figure 4) (P ≤ 0.025), by host cells (in PAI-1-Tg mice) or by both tumor cells and host 
cells (Figure 2). 
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Figure 3 PAI-1 expression and in vitro invasion of PAI-1 transfected PDVA cells. Cells were transfected with 
pCDNA-3.1 vector alone (Invitrogen) or pCDNA-3.1 vector containing the full length cDNA of murine PAI-1. 
Stable populations of cells overexpressing PAI-1 ('PDVA PAI-1 ') and their corresponding control cells ('PDVA-
CTL') were selected with the neomycin-analogous G418 (400µg/ml; GIBCO BRL). (a) RT-PCR analysis of PAI-
1 expression in PAI-1-transfected cells (lane 2) and control cells (lane 1). RT-PCR products were separated on 
10% acrylamide gels and analysed using a Fluor-S Multilmager (Bio-Rad, Hercules, CA, USA) after staining 
with Gelstar dye (FMC BioProducts, Rockland, ME, USA). The expected product size is 197bp for murine PAI-1 
and 212bp for murine 28S. (b) In vitro invasion test. Cells (6 x 104) suspended in 300 µl of serum-free medium 
containing 0.1% (w/v) bovine serum albumin (fraction V, Sigma) were seeded in the upper compartment of 
Transwell cell culture inserts (8 µm pore size, Costar, Cambridge, MA, USA) coated with Matrigel (25 µg/filter). 
The lower compartment contained DMEM supplemented with 20% serum and 1% BSA. Results expressed as 
mean cell number in the lower face of a filter ( x 400) (from triplicate samples) are those of one representative 
experiment among three separate assays 
 
 
Figure 4 Analysis of tumor cell invasion (a) and angiogenesis (b) of PDVA cell overexpressing PAI-1 or control 
cells. PDVA cells ('CTL') or PAI-1 cDNA-transfected cells ('PAI-1') were transplanted into wild-type mice (WT), 
transgenic mice (Tg-PAI-1) and PAI-1-deficient mice (PAI-1-/-). Tumor invasion (i) and angiogenesis (a) were 
determined as described in Figure 2 legend 
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To determine whether PAI-1 produced by tumor cells could compensate for the absence of host PAI-1, PAI-1- 
overexpressing PDVA cells were also transplanted into PAI-1-deficient mice. Interestingly, whatever the 
amounts of PAI-1 produced by tumor cells, blood vessels remained below the collagen gel and tumor cells failed 
to invade the PAI-1-deficient host tissue. These findings clearly demonstrate that the specific site of PAI-1 
production (stromal cells rather than tumor cells) is a critical factor in tumor angiogenesis rather than the total 
amount of PAI-1 in tumor. 
The proangiogenic effect of PAI-1 produced by host cells could be related to a protection of the extracellular 
matrix against an excessive degradation induced by tumor cells. Our previous work demonstrated that the 
function of PAI-1 in angiogenesis was related to controlled plasmin-mediated proteolysis during tumoral 
angiogenesis, rather than to a modulation of cell interaction with vironectin (Bajou et al., 2001). PAI-1 might 
stabilize the matrix scaffold required for endothelial cell migration and the assembly of endothelial cells into 
capillaries (Montesano et al., 1990). Indeed, a critical balance between proteases and their inhibitors is thought to 
be essential for optimal angiogenesis (Pepper and Montesano, 1990) and tumor cell invasion (Liu et al., 1995). 
The sequestration of PAI-1 in the matrix is consistent with such a role (Bajou et al., 1998). This model implies 
that angiogenesis requires PAI-1 levels within an optimal range and fits perfectly with the present demonstration 
of a dose-dependent effect of PAI-1 on angiogenesis. 
The antiangiogenic effect of PAI-1 used at therapeutical concentrations agreed with the data reported in the 
CAM, Matrigel implant and aortic ring assays (McMahon et al., 2001; Stefansson et al., 2001; Devy et al., 
2002). Accordingly, when PDVA cells were transfected with murine PAI-1 cDNA to overproduce PAI-1, a 
significant reduction of tumor cell invasion was observed in vivo after transplantation into WT mice. This effect 
could be ascribed to a reduced capacity of invasion as assessed in vitro in Transwell assay. These findings are in 
accordance with the results obtained after PAI-1 transfection of human prostate carcinoma cells and showing a 
reduction in tumor-associated angiogenesis (Soff et al., 1995). 
The present study highlights for the first time the importance of local variations of PAI-1 concentration and of 
the cellular source of PAI-1 (tumor cells versus host cells) for its opposite effects in vivo on tumor invasion and 
vascularization. Our demonstration of a dose-dependent effect of PAI-1 on tumoral angiogenesis confirms our 
previous observations in another pathological angiogenic process, the choroidal neoangiogenesis (Lambert et al., 
2003). Altogether, these findings have important implications in antiangiogenic strategies and sound a note of 
warning for the pharmacological use of PAI-1 agonists/antagonists. 
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